Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference

Rhea-AI Summary

Shattuck Labs, Inc. (STTK) to participate in the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023, featuring a fireside chat with Dr. Taylor Schreiber, the company's CEO. The presentation will focus on the development of bi-functional fusion proteins for cancer and autoimmune disease treatment. A live webcast and replay will be available on the company's website.

AUSTIN, TX & DURHAM, NC, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in the 6^th Annual Evercore ISI HealthCONx Conference being held November 28-30, 2023.

Presentation Details
Conference: 6^th Annual Evercore ISI HealthCONx Conference
Format: Fireside chat with covering analyst, Jonathan Miller, Ph.D.
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Date: November 29, 2023
Time: 9:10 a.m. ET

A live webcast of the fireside chat will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation date.

About Shattuck Labs, Inc.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, (“ARC®”), platform are designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company’s lead SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

FAQ

What is the 6th Annual Evercore ISI HealthCONx Conference?

The 6th Annual Evercore ISI HealthCONx Conference is an industry event where Shattuck Labs, Inc. will participate in a fireside chat presentation.

Who will be presenting at the conference?

Dr. Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer, will be presenting at the conference.

What is the focus of the presentation?

The presentation will focus on the development of bi-functional fusion proteins as a new class of biologic medicine for cancer and autoimmune disease treatment.

Where can the webcast of the fireside chat be accessed?

The live webcast and replay will be available on the Events & Presentations section of Shattuck Labs, Inc.'s website.